Regentis Biomaterials director files initial Form 3

REGENTIS BIOMATERIALS LTD. director Efraim Cohen-Arazi has filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider.

Accepted by SEC EDGAR 03/18/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

REGENTIS BIOMATERIALS LTD. director Efraim Cohen-Arazi has filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider. The filing establishes his reporting status as a director of the company but does not show any transactions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the REGENTIS BIOMATERIALS (RGNT) Form 3 filing show?

The Form 3 shows that Efraim Cohen-Arazi is a director at REGENTIS BIOMATERIALS LTD. It records his status as an insider but includes no reported transactions or derivative positions in this filing excerpt.

Who is the reporting person in the REGENTIS BIOMATERIALS (RGNT) Form 3?

The reporting person is Efraim Cohen-Arazi, identified as a director of REGENTIS BIOMATERIALS LTD. The filing confirms his role as an insider required to report holdings and future trades under SEC rules.

Does the REGENTIS BIOMATERIALS (RGNT) Form 3 report any stock transactions?

No, this Form 3 excerpt does not report any stock transactions. It only serves as an initial statement of beneficial ownership, with transaction counts and share amounts all shown as zero in the summary data provided.

Are any derivative securities reported in the REGENTIS BIOMATERIALS (RGNT) Form 3?

No derivative securities are reported in this Form 3 excerpt. The derivativeSummary section is empty and the exercise-related counts in the transaction summary are all zero, indicating no options or similar instruments are listed here.

What is the significance of a Form 3 for REGENTIS BIOMATERIALS (RGNT) investors?

A Form 3 marks when someone becomes an insider obligated to report holdings and trades. For REGENTIS BIOMATERIALS, it shows Efraim Cohen-Arazi’s director status, laying the groundwork for tracking any future Form 4 or Form 5 transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cohen-Arazi Efraim

(Last) (First) (Middle)

C/O REGENTIS BIOMATERIALS LTD.

60 MEDINAT HAYEHUDIM

(Street)

HERZLIYA 4676652

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
REGENTIS BIOMATERIALS LTD. [ RGNT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Efraim Cohen-Arazi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)